CL2022001377A1 - Compuestos agonistas de tlr7, composiciones y uso para tratar cáncer y enfermedades infecciosas. - Google Patents

Compuestos agonistas de tlr7, composiciones y uso para tratar cáncer y enfermedades infecciosas.

Info

Publication number
CL2022001377A1
CL2022001377A1 CL2022001377A CL2022001377A CL2022001377A1 CL 2022001377 A1 CL2022001377 A1 CL 2022001377A1 CL 2022001377 A CL2022001377 A CL 2022001377A CL 2022001377 A CL2022001377 A CL 2022001377A CL 2022001377 A1 CL2022001377 A1 CL 2022001377A1
Authority
CL
Chile
Prior art keywords
compositions
infectious diseases
treating cancer
agonist compounds
tlr7 agonist
Prior art date
Application number
CL2022001377A
Other languages
English (en)
Inventor
Stephen E Webber
James Richard Appleman
Original Assignee
Primmune Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Primmune Therapeutics Inc filed Critical Primmune Therapeutics Inc
Publication of CL2022001377A1 publication Critical patent/CL2022001377A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

COMPUESTOS AGONISTAS DE TLR7, COMPOSICIONES Y USO PARA TRATAR CÁNCER Y ENFERMEDADES INFECCIOSAS.
CL2022001377A 2019-11-26 2022-05-25 Compuestos agonistas de tlr7, composiciones y uso para tratar cáncer y enfermedades infecciosas. CL2022001377A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962940622P 2019-11-26 2019-11-26

Publications (1)

Publication Number Publication Date
CL2022001377A1 true CL2022001377A1 (es) 2023-04-10

Family

ID=75974715

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022001377A CL2022001377A1 (es) 2019-11-26 2022-05-25 Compuestos agonistas de tlr7, composiciones y uso para tratar cáncer y enfermedades infecciosas.

Country Status (17)

Country Link
US (2) US11692005B2 (es)
EP (1) EP4065155A4 (es)
JP (1) JP2023503996A (es)
KR (1) KR20220150879A (es)
CN (1) CN115427063A (es)
AU (1) AU2020391487A1 (es)
BR (1) BR112022010165A2 (es)
CA (1) CA3163093A1 (es)
CL (1) CL2022001377A1 (es)
CO (1) CO2022008835A2 (es)
CR (1) CR20220282A (es)
EC (1) ECSP22049906A (es)
IL (1) IL293293A (es)
MX (1) MX2022006307A (es)
PE (1) PE20221324A1 (es)
TW (1) TW202134240A (es)
WO (1) WO2021108649A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114917228B (zh) * 2022-06-07 2023-09-26 广西中医药大学 一种用于预防性治疗狂犬病的药方及其制备方法与应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5476659A (en) 1982-11-09 1995-12-19 The Scripps Research Institute Cancerous B cell treatment using substituted nucleoside derivatives
US5011828A (en) 1985-11-15 1991-04-30 Michael Goodman Immunostimulating guanine derivatives, compositions and methods
US5136030A (en) 1988-05-05 1992-08-04 Scripps Clinic And Research Foundation Immunostimulating guanine derivatives, compositions and methods
US5093319A (en) 1989-10-31 1992-03-03 Pfizer Hospital Products Group, Inc. Use of derivatives of chitin soluble in aqueous solutions for preventing adhesions
AU5845594A (en) 1992-11-13 1994-06-08 Scripps Research Institute, The Cancerous b cell treatment using substituted nucleoside derivatives
CZ126799A3 (cs) 1996-10-16 1999-07-14 Icn Pharmaceuticals Purinové L-nukleosidy a jejich analogy a farmaceutické prostředky, které je obsahují
TR200601782T2 (tr) 1999-11-12 2006-09-21 Pharmasset Ltd. 2'-Deoksi-L-Nükleositlerin sentezi.
CN1427722A (zh) 2000-02-18 2003-07-02 希拉生物化学股份有限公司 用核苷类似物治疗或预防黄病毒感染的方法
EP1411954B1 (en) 2000-10-18 2010-12-15 Pharmasset, Inc. Modified nucleosides for treatment of viral infections and abnormal cellular proliferation
OA13310A (en) 2003-09-05 2007-04-13 Anadys Pharmaceuticals Inc TLR7 ligands for the treatment of hepatitis C.
PT1824482E (pt) * 2004-12-17 2014-05-13 Anadys Pharmaceuticals Inc Compostos 3h-oxazolo e 3h-tiazolo[4,5-d]pirimidin-2-ona 3,5- -di-substituídos e 3,5,7-tri-substituídos e seus pró- -fármacos
WO2009023819A2 (en) 2007-08-15 2009-02-19 Idera Pharmaceuticals, Inc. Toll like receptor modulators
EP2313111B1 (en) * 2008-08-01 2013-09-04 Ventirx Pharmaceuticals, Inc. Toll-like receptor agonist formulations and their use
WO2010111290A1 (en) 2009-03-23 2010-09-30 University Of Utah Research Foundation Methods and compositions related to modified guanine bases for controlling off-target effects in rna interference
IN2014CN04251A (es) 2011-11-09 2015-07-17 Ascend Biopharmaceuticals Ltd
EP4001311A1 (en) 2014-07-09 2022-05-25 Birdie Biopharmaceuticals Inc. Anti-pd-l1 combinations for treating tumors
RS61612B1 (sr) 2014-12-08 2021-04-29 Hoffmann La Roche 3-supstituisana 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-dion jedinjenja za lečenje i profilaksu virusne infekcije
KR20170113658A (ko) 2015-03-16 2017-10-12 에프. 호프만-라 로슈 아게 Tlr7 작용제 및 hbv 캡시드 조립 억제제를 사용하는 병용 치료
CN106943596A (zh) 2016-01-07 2017-07-14 博笛生物科技（北京）有限公司 用于治疗肿瘤的抗-cd20组合
CN110177791B (zh) * 2016-12-20 2022-07-12 阿斯利康(瑞典)有限公司 氨基-三唑并吡啶化合物及其在治疗癌症中的用途
SG11202011667WA (en) * 2018-05-25 2020-12-30 Primmune Therapeutics Inc Tlr7 agonists

Also Published As

Publication number Publication date
WO2021108649A1 (en) 2021-06-03
EP4065155A4 (en) 2023-11-29
EP4065155A1 (en) 2022-10-05
CN115427063A (zh) 2022-12-02
TW202134240A (zh) 2021-09-16
US20240116974A1 (en) 2024-04-11
KR20220150879A (ko) 2022-11-11
US11692005B2 (en) 2023-07-04
IL293293A (en) 2022-07-01
JP2023503996A (ja) 2023-02-01
AU2020391487A1 (en) 2022-07-07
US20210155652A1 (en) 2021-05-27
CR20220282A (es) 2022-11-28
MX2022006307A (es) 2022-08-22
PE20221324A1 (es) 2022-09-09
ECSP22049906A (es) 2022-07-29
CO2022008835A2 (es) 2022-07-19
BR112022010165A2 (pt) 2022-08-09
CA3163093A1 (en) 2021-06-03

Similar Documents

Publication Publication Date Title
CO2020009861A2 (es) Inhibidores pd-1/pd-l1
CO2020016619A2 (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso
DOP2019000266A (es) Inhibidores de pd-1/pd-l1
CO2018009275A2 (es) Derivados pirrolidina espiro-condensados como inhibidores de enzimas desubiquitinantes (dub)
CL2018001152A1 (es) Composiciones y métodos para el tratamiento del cáncer
CR20190318A (es) Compuestos heterocíclicos como inmunomoduladores
AU2017319323A8 (en) Biaryl compounds useful as immunomodulators
CO2017010890A2 (es) Derivados de maitansinoide, conjugados del mismo, y metodos de uso
ECSP20046463A (es) Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas
JOP20200152A1 (ar) مركبات حلقية كبرى لعلاج مرض
MX2018009633A (es) Inhibidor de indoleamina-2,3-dioxigenasa (ido).
EA201792231A1 (ru) Ингибиторы индоламин-2,3-диоксигеназы и способы их применения
UY34750A (es) ?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?.
EA201690027A1 (ru) Ингибиторы ido
CL2021003513A1 (es) Compuestos heterocíclicos, como inhibidores de bet; composición, útil para tratar cáncer.
CO2021002977A2 (es) Dimetilaminoazetidinaminas como inhibidores de jak
BR112019017403A2 (pt) composições e métodos para o tratamento de câncer
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
BR112017022281A2 (pt) métodos para tratar câncer
CO2022000481A2 (es) Inhibidores de enzimas
CO2022006466A2 (es) Inhibidores de egfr alostéricos y métodos de uso de los mismos
NI201500175A (es) Compuestos nuevos para el tratamiento del cáncer
CO6721048A2 (es) Anticuerpos que se unen a notum pectinacetilesterasa
BR112017022269A2 (pt) métodos para tratar câncer
CL2022001377A1 (es) Compuestos agonistas de tlr7, composiciones y uso para tratar cáncer y enfermedades infecciosas.